Oncoinvent appoints Zuzana Jiráková Trnková as chief medical officer

PUBT · 2d ago
Oncoinvent appoints Zuzana Jiráková Trnková as chief medical officer
  • Oncoinvent appointed Zuzana Jiráková Trnková chief medical officer, effective November 4, 2026, to lead Radspherin Phase 3 preparations.
  • She succeeds Kari Myren, who will leave to pursue an opportunity outside drug discovery.
  • Jiráková Trnková most recently served as Highlight Therapeutics’ chief medical officer, bringing over 20 years of clinical development experience.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncoinvent ASA published the original content used to generate this news brief via Cision (Ref. ID: 202610280200BITN____UKPR__EN_20261027-BIT-0851-0) on October 28, 2026, and is solely responsible for the information contained therein.